middle.news
How Will Cleo’s $5M Raise Accelerate Its U.S. Ovarian Cancer Test Launch?
10:02am on Thursday 18th of December, 2025 AEDT
•
Healthcare
Read Story
How Will Cleo’s $5M Raise Accelerate Its U.S. Ovarian Cancer Test Launch?
10:02am on Thursday 18th of December, 2025 AEDT
Key Points
Raised $5 million via placement at $0.60 per share
Funds allocated to U.S. market entry and commercial launch
Accelerated development of high-value ovarian cancer screening test
Placement attracted new institutional and existing shareholders
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE